The Stat3 inhibitor F0648-0027 is a potential therapeutic against rheumatoid arthritis
Yosuke Kaneko(Keio University), Takeshi Miyamoto(Kumamoto Health Science University), Shin-ichiro Ozawa(Kitasato University), Masaya Nakamura(Keio University), Kengo Harato(Keio University), Yasuo Niki(Fujita Health University), Tami Kobayashi(Keio University), Morio Matsumoto(Keio University Hospital), Shu Kobayashi(Keio University), Shuichi Hirono(Kitasato University), Tatsuaki Matsumoto(Keio University), Yuiko Sato(Keio University), Kana Miyamoto(Kumamoto University)
Cited by 0
Related Papers
DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells
|The Journal of Experimental Medicine|2005|899
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis
|Cell Metabolism|2006|771
Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors
|The Journal of Experimental Medicine|1999|694
v-ATPase V0 subunit d2–deficient mice exhibit impaired osteoclast fusion and increased bone formation
|Nature Medicine|2006|542
Transient receptor potential (<scp>TRP</scp>) channels: a clinical perspective
|British Journal of Pharmacology|2013|362